Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOPAR vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Acne vulgaris,Brucellosis,Cholera,Granuloma inguinale,Listeriosis,Lymphogranuloma venereum,Mycoplasma pneumoniae infection,Psittacosis,Q fever,Rocky Mountain spotted fever,Syphilis (when penicillin contraindicated),Trachoma,Tularemia,Urinary tract infections (caused by susceptible organisms)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
500 mg orally twice daily for 7-14 days.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Tetracycline is not extensively metabolized; primarily excreted unchanged in urine and feces.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal (80-90% unchanged), fecal (10-20%)
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
25-30% bound to albumin
Approximately 90–95% bound, primarily to albumin.
0.2-0.3 L/kg (suggests low tissue penetration; primarily extracellular fluid)
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 60-75%; IM: ~100%
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Cr Cl 30-50 m L/min: 500 mg once daily; Cr Cl 15-29 m L/min: 250 mg once daily; Cr Cl <15 m L/min or on dialysis: 250 mg every 48 hours.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
No adjustment required for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): use with caution; consider reduced dose.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
For children >1 year: 15 mg/kg/day divided every 12 hours, not to exceed 500 mg per dose.
Not established; safety and efficacy not studied in pediatric patients.
No specific dose adjustment based on age alone; dose based on renal function. Use minimum effective dose and monitor renal function.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Tetracycline use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
None
Photosensitivity: exaggerated sunburn reaction may occur.,Hepatotoxicity: rare but can occur, especially in patients with renal impairment.,Renal impairment: may require dose adjustment; avoid in severe renal dysfunction.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea may occur.,Superinfection: overgrowth of nonsusceptible organisms including fungi.,Use in pregnancy: category D; avoid due to risk to fetus.,Use in children <8 years: avoid due to tooth discoloration and bone growth inhibition.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to tetracycline or any component,Pregnancy (last half),Children under 8 years,Severe hepatic or renal impairment
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum within 2 hours of taking cyclopar. Iron supplements, zinc, and bismuth subsalicylate also reduce absorption. Take with a full glass of water; avoid concurrent intake of high-iron foods (e.g., spinach, red meat) within 1-2 hours. No significant interaction with alcohol but caution due to potential hepatotoxicity.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, tetracyclines can cause reversible inhibition of fetal bone growth. Avoid during pregnancy; alternative antibiotics should be selected.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Tetracyclines are excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.5. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. However, due to poor oral absorption and binding to milk calcium, systemic exposure is minimal. Use is generally considered compatible with breastfeeding if short-term; caution is advised with prolonged therapy.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No pharmacokinetic data specifically for pregnancy; standard adult dosing may be used if absolutely necessary, but use is discouraged. If unavoidable, monitor serum levels (therapeutic range 5–10 mcg/m L) as pregnancy-induced changes in volume of distribution and renal clearance may alter drug exposure. Dose adjustments should be guided by clinical response and serum levels.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Cyclopar (tetracycline) should be taken on an empty stomach 1 hour before or 2 hours after meals to enhance absorption. Avoid concurrent use with dairy products, antacids, or iron supplements due to chelation. Photosensitivity is common; advise sun protection. Monitor for superinfection, especially C. difficile colitis. Use with caution in renal impairment; adjust dose to avoid nephrotoxicity. Not recommended in children under 8 years or during pregnancy due to bone and teeth discoloration.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take this medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium-rich foods for at least 2 hours before and after taking this drug.,This drug can make your skin more sensitive to sunlight; use sunscreen, wear protective clothing, and avoid tanning beds.,Complete the full course of treatment even if you feel better; do not skip doses.,Inform your doctor if you experience severe diarrhea, vaginal itching, or oral thrush as these may indicate a secondary infection.,Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor.,Store at room temperature away from moisture and heat. Do not use outdated tetracycline as it can become toxic.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOPAR vs CHLORZOXAZONE, answered by our medical review team.
CYCLOPAR is a Muscle Relaxant that works by Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOPAR and CHLORZOXAZONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOPAR is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOPAR and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOPAR is classified as Category C. Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gr. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.